

1 The effects of the infarct volume on cytokines and
2 immune status in patients with acute ischemic stroke

3 **Short title: The immune status of patients with acute cerebral infarction is**
4 **related to the infarct volume**

5 Author: Xingqi Su¹, Lingmin Zhao¹, Di Ma^{1*}, Jiulin You¹, Liangshu Feng¹, Jing
6 wang¹, YuLei Hao¹, XinYu Wang¹, JiaChun Feng¹

7
8
9 ¹ Affiliation: Bethune First Hospital, Jilin University, Changchun, China

10 * Corresponding author: Di Ma, LiJuan Wang

11 Email:

12 madi2017@jlu.edu.cn (M.D)

13 wanglj66@jlu.edu.cn (W.Lj)

14
15 **Abstract**

16 **Objective:** To investigate and analyze the effects of the infarct volume on cytokines
17 and immune status in patients with acute ischemic stroke. **Methods:** Patients with acute
18 ischemic stroke that presented within 72 h of onset from October 2017 to October 2019
19 were enrolled. Patients with severe cerebral infarction (large-area cerebral infarction)
20 (n=34) were enrolled and categorized as group A; Additionally, 33 patients with non-
21 large-area cerebral infarction with matching baseline characteristics (sex and age) to
22 group A were included in group B. We measured IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-
23 α , and IFN- γ levels in serum using a cytometric bead array. In addition, we compared
24 the absolute value of lymphocytes (LYM#), lymphocyte percentage (LYM%),

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 neutrophil/lymphocyte ratio (NLR), cytokine levels, and immune status indicators
26 (IFN- γ IL-4 ratio, TNF- α /IL-4 ratio, and TNF- α /IL-10 ratio) between groups A and B,
27 and evaluated the effect of infarct size on inflammatory factors and immune status.
28 **Results:** Compared with group B, the LYM# and LYM% in group A were significantly
29 lower, and the NLR and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF- α , and IFN-
30 γ) levels were significantly higher. TNF- α /IL-4 ratio was significantly lower, and the
31 IFN- γ /IL-4 ratio (P=0.09) and TNF- α /IL-10 ratio (P=0.146) in group A demonstrated a
32 decreasing trend although not significant. **Conclusions:** The immune status of patients
33 with acute cerebral infarction is related to the infarct volume; patients with large-area
34 cerebral infarction are more likely to develop immunosuppression.

35

36 Key words

37 Acute cerebral infarction, immunity, inflammation, cytokines, inflammatory
38 cells, infarct volume

39

40 1. Introduction

41 According to the all-cause mortality statistics of the World Health Organization
42 (WHO), stroke is the second leading cause of death globally, accounting for 87%[1],
43 and its high disability rate significantly increases the social burden. Because immunity
44 is crucial in cerebral infarction and, in turn, is regulated by it, the immune mechanism
45 has become a target that may benefit clinical treatment and has attracted increasing
46 interest from researchers.

47 Notably, immunity is crucial in the occurrence, progression, and outcome of
48 ischemic stroke. The basic pathology of atherosclerotic cerebral infarction is

49 atherosclerosis. Various immune cells, including lymphocytes and mononuclear
50 macrophages, are involved in the formation of atherosclerotic plaques and the rupture
51 of unstable plaques[2,3], an important cause of atherosclerotic cerebral infarction[4].
52 Immunity contributes to the pathogenesis of cerebral infarction and affects
53 prognosis[5–8]. After local cerebral infarction, astrocytes and microglia, which are
54 involved in the release of cytokines and chemokines[9], are rapidly activated, attract
55 immune cells from the peripheral circulation to the ischemic area, and participate in
56 inflammatory damage to the brain tissue[10]. In addition, in the recovery from chronic
57 cerebral infarction, the immune status affects the brain tissue microenvironment,
58 regulates neurogenesis[11,12] and angiogenesis[13], and affects the autoimmune
59 response to brain tissue antigens after stroke, mediating the long-term prognosis[5,6].
60 Notably, as a stress event, ischemic stroke regulates systemic immunity through the
61 sympathetic nervous system and the hypothalamus-pituitary-adrenal axis, which is an
62 important mechanism of post-stroke immunosuppression, leading to increase mortality
63 of patients with acute cerebral infarction [7,8,16-19]. We know that the size of different
64 infarcts also affects the treatment and prognosis of acute ischemic
65 stroke,(PMED: 28665171)In this study, we investigate and analyze the effects of the
66 infarct volume on cytokines and immune status in patients with acute ischemic
67 stroke.This enables the clinicians to make informed decisions in selecting
68 immunotherapy approaches and tailor rehabilitation strategies to optimize patient
69 outcomes by considering different infarct sizes.

70

71 **2. Materials and methods**

72 **2.1 Research objects and samples**

73 Inclusion criteria:

- 74 1. Patients with acute ischemic stroke presenting with an onset time of ≤ 72 h in
75 the Department of Neurology of the First Hospital of Jilin
76 University(Changchun,China) from October 2017 to October 2019.
- 77 2. Patients who voluntarily participated in the study.
- 78 3. Patients aged 18–80 years old, regardless of sex.

79 Exclusion criteria:

- 80 1. Intracranial artery dissection, aneurysm, vascular inflammatory diseases,
81 vascular malformations, and other neurological diseases.
- 82 2. Patients who have undergone thrombolysis or thrombectomy.
- 83 3. Patients with or suspected cerebral embolism.
- 84 4. Abnormal liver and kidney function; AST or ALT 3 times higher than the upper
85 limit of normal value; creatinine clearance rate of < 0.6 mL/s; blood creatinine
86 level > 265 $\mu\text{mol/L}$.
- 87 5. Patients with autoimmune diseases, who have received immunotherapy, or with
88 malignant tumors.
- 89 6. Patients with severe trauma or have undergone major surgery recently.

90 Sample collection:

91 Peripheral blood (2–3 mL) of the patients were collected immediately after
92 admission using a coagulation blood collection tube. After centrifugation (4 °C, 3000
93 r/min, 5 min), the supernatant (serum samples) was collected and cryopreserved at -
94 80 °C.

95 **2.2 Reagents and equipment:**

96 BD FACS Calibur flow cytometer (BD Company, USA); low-temperature high-
97 speed centrifuge (Heraeus Sepaech, Germany); low-temperature refrigerator (Haier

98 Company, Qingdao, China); BD™ Cytometric Bead Array (CBA) human
99 Th1/Th2/Th17 kit (BD Company, USA); BD™ Cytometric Bead Array (CBA) Human
100 Soluble Protein Master Buffer kit, (BD Company, USA).

101 **2.3 Determination of cytokines in serum samples by CBA**

102 **method**

103 The BD™ Cytometric Bead Array (CBA) human Th1/Th2/Th17 kit was used to
104 determine the cytokine (IL-2, IL-6, IL-4, IL-10, IL-17A, IFN- γ , TNF- α) levels in each
105 serum sample according to the manufacturer's instructions.

106 **2.4 Experimental group**

107 A total of 67 patients presenting with an onset time of 72 h were included in this
108 study; patients with large-area cerebral infarction were included in the large-area
109 cerebral infarction group and categorized as group A. A total of 34 patients, including
110 patients with anterior circulation infarction and posterior circulation infarction, were
111 included. For anterior circulation infarction, the maximum diameter of the infarct
112 was >3 cm (25 participants), and regarding posterior circulation infarction, the
113 maximum infarction cross-section was $>1/3$ of the brainstem (9 participants).

114 Additionally, 33 patients with non-large-area cerebral infarction with matching
115 sex and age with Group A were included in the non-large-area cerebral infarction group
116 and categorized as Group B, including patients with anterior circulation infarction and
117 posterior circulation infarction. For anterior circulation infarctions, the largest infarct
118 diameter was <3 cm (27 participants), and for posterior circulation infarctions, the
119 largest brainstem infarct area was $<1/3$ of the cross-sectional area (6 participants).

120 **2.5 Statistical analysis and graph**

121 Statistical analysis was performed using IBM SPSS Statistics version 25.0 (IBM

122 Corp., Armonk, N.Y., USA), and GraphPad Prism version 7 (GraphPad Software, Inc.,
123 La Jolla, CA, USA) was used for graphing. The counted data were presented as the
124 number of cases (n) and percentages (%). Measurement data with normal distribution
125 are presented as $\bar{x} \pm s$ and measurement data that are not normally distributed are
126 presented as the median and quartile M (Q25–Q75). For counting data, the Chi-square
127 test (χ^2 test) was used to compare groups. For the comparison between the two groups
128 of measurement data, the t-test was used for normally distributed data, and the
129 nonparametric rank-sum test (Mann–Whitney U test) was used for non-normal
130 distribution. For the comparison between the three groups of measurement data, a one-
131 way analysis of variance (ANOVA) was used for the normal distribution, and the
132 variance was uniform. The LSD-t test was used for the pairwise comparison of the mean
133 between the groups.

134 The groups showed statistically significant differences, with a P-value of <0.05
135 indicating statistical significance; for pairwise comparison of the mean between the
136 groups, the statistical difference was based on the unadjusted P-value <0.017 and the
137 adjusted P-value <0.05.

138 **3. Results**

139 We compared the expression levels of various cytokines, including IL-2, IL-4, IL-
140 6, IL-10, and IL17A, in the large-area infarction group (group A) and the non-large-
141 area infarction group (group B) based on the same baseline level. Furthermore, we
142 compared the absolute lymphocyte value (LYM#), lymphocyte ratio lymphocyte
143 percentage (LYM%), neutrophil/lymphocyte ratio (NLR), IFN- γ /IL-4 ratio, TNF- α /IL-
144 4 ratio, and TNF- α /IL-10 ratio between groups A and B.

145 The results indicated the following: (1) The cytokine levels in group A were
146 significantly higher than in group B, as shown in Table 2 and Fig 1. These differences

147 were considered statistically significant; $P < 0.05$. (2) Group A exhibited significantly
148 lower LYM# and LYM% than group B, and the NLR was significantly higher. These
149 findings are presented in Table 3 and Fig 2 and showed statistically significant
150 differences. (3) The TNF- α /IL-4 ratio in group A was significantly lower than in group
151 B, which showed a statistically significant difference. The TNF- α /IL-10 ratio and IFN-
152 γ /IL-4 ratio in group A demonstrated a decreasing trend but showed no statistically
153 significant differences (Table 4 and Fig 3).

154

155 **Table 1. Baseline data between patients in group A and group B.**

Baseline	Group A	Group B	P-value
Sex, Male (n, %)	19 (55.88%)	24 (72.7%)	0.151
Female (n, %)	15 (44.12%)	9 (27.3%)	
Hypertension (n, %)	23 (67.65%)	26 (78.79%)	0.304
Diabetes (n, %)	10 (29.42%)	10 (30.30%)	0.936
Smoking history (n, %)	14 (41.17%)	13 (39.39%)	0.882
Age (years)	63.5 (57–69)	62.5 (56.25–69)	0.768
LDL-C (mmol/L)	3.06 (2.72–4.34)	2.9 (2.29–3.86)	0.075
Hcy (μ mol/L)	14.45 (10.93–19.65)	15.3 (13.4–20.8)	0.166
Fasting blood glucose (mmol/L)	5.84 (5.23–7.93)	5.71 (4.96–6.61)	0.349
NIHSS score	13 (11–16.25)	4 (3–8)	0.000

156

157

158 **Table 2. Serum cytokine levels of patients of group A and group B.**

Cytokine level	Group A	Group B	U-value	P-value
IL-6 (pg/mL)	32.35 (9.69–56.60)	9.81 (3.09–28.60)	320.00	0.003
IL-4 (pg/mL)	4.02 (3.45–4.76)	0.58 (0.31–0.80)	27.00	0.000
IL-2 (pg/mL)	1.96 (1.75–2.19)	0.55 (0.32–0.98)	84.50	0.000
IL-17A (pg/mL)	8.15 (6.30–9.66)	3.25 (1.37–5.08)	142.00	0.000
IFN-γ (pg/mL)	2.58 (2.30–2.99)	0.61 (0.22–0.95)	13.00	0.000
TNFα (pg/mL)	2.63 (2.23–3.15)	1.71 (0.80–2.82)	284.00	0.001
IL-10 (pg/mL)	3.43 (2.66–4.52)	1.31 (0.89–2.46)	169.00	0.000

159 Mann–Whitney U test was used. The cytokine levels in group A were significantly
160 higher than in group B.

161

162

163 **Fig 1. Serum cytokine levels of groups A and group B patients.**

164 ** P<0.01.

165

166 **Table 3. LYM#, LYM%, and NLR between group A and group B.**

Indicators	Group A	Group B	U-value	P-value
LYM# ($\times 10^9$)	1.41 (1.05–1.79)	1.76 (1.43–2.35)	324.50	0.003
LYM%	0.14 (0.08–0.22)	0.26 (0.21–0.33)	214.00	0.000
NLR	5.27 (3.26–10.79)	2.61 (1.73–3.36)	204.00	0.000

167 Mann–Whitney U test was used. The LYM# and LYM% of the large-area group (group
168 A) were significantly lower than those of the non-large-area group (group B), while the
169 NLR of group A was significantly higher than that of group B.

170

171

172

Fig 2. LYM#, LYM%, NLR of group A and group B.

173

** P<0.01

174

175

Table 4. Indicators of immune status of patients in group A and group B.

Indicators	Group A	Group B	U-value	P-value
TNF-α/IL-4	0.69 (0.54–0.83)	2.50 (1.62–5.99)	137.00	0.000
TNF-α/IL-10	0.80 (0.53–1.12)	1.05 (0.53–3.06)	445.00	0.146
IFN-γ/IL-4	0.66 (0.52–0.82)	1.07 (0.40–2.06)	426.00	0.090

176

Mann–Whitney U test was used. The TNF- α /IL-4 ratio in group A was significantly

177

lower than in group B; the TNF- α /IL-10 and IFN- γ /IL-4 ratios in group A showed a

178

downward trend.

179

180

Fig 3. Immune status of patients in group A and group B.

181

** P<0.01.

182

183 **4. Discussion**

184

Ischemic stroke is a common cerebrovascular disease; it causes irreversible brain

185

tissue damage. The complex pathological mechanism includes excitatory glutamate

186

toxicity, calcium overload, oxidative stress, and inflammatory damage.

187

Inflammatory reaction is crucial in brain tissue injury following infarction. The

188

immune state regulates local pathophysiological changes and significantly affects the

189

outcome of ischemic tissues. The proinflammatory state aggravates local injury;

190

however, the anti-inflammatory state protects the local brain tissue, promotes the

191

removal of necrotic cells, and prevents further damage. Inflammation of the central

192

nervous system and peripheral systemic immunity are closely linked and reflect the

193 delicate and ingenious integrity of the human body. For example, the blood-brain
194 barrier (BBB) is compromised after cerebral infarction and peripheral immune cells
195 invade the brain tissue. The Th cells that invade the central nervous system secrete
196 several cytokines and interact with microglia to initiate microglial polarization [14,15];
197 this affects the degree and outcome of the local brain tissue damage.

198 The relationship between the nervous and immune systems is such that the
199 immune system affects the pathophysiological changes of cerebral infarction and is, in
200 turn, affected by cerebral infarction events, such as immunosuppression after stroke.
201 The underlying mechanism is not fully understood. Post-stroke immunosuppression is
202 a self-protective mechanism for suppressing central inflammation; however, it alters
203 peripheral immune status and further affects the prognosis in patients with acute
204 cerebral infarction[7–8].

205 Considering the role of immune factors in the course of cerebral infarction,
206 investigating the immune mechanisms has increasingly attracted the interest of
207 researchers. The body's immunity is affected by several factors, and some related
208 factors can be controlled artificially; therefore, the immune mechanism may be a
209 potential clinical treatment target. In this study, we evaluated the levels of various
210 cytokines, including IL-2, IL-6, TNF- α , IFN- γ , IL-4, IL-10, and IL-17A in patients
211 presenting with acute cerebral infarction within 72 h of onset, and calculated the INF-
212 γ /IL-4, TNF- α /IL-4, and TNF- α /IL-10 ratios. The IFN- γ /IL-4 ratio indicates the balance
213 between the subpopulations of helper T cells, reflecting the relative function between
214 the Th1 and Th2 subpopulations. IFN- γ is an essential proinflammatory cytokine
215 secreted by Th1-type cells, while IL-4 is a relatively specific cytokine of Th2-type cells
216 and exerts an anti-inflammatory effect. The initial Th cells, Th0 cells, are regulated by
217 several factors and differentiated into subpopulations. The most significant factor is the

218 type and level of cytokines and the balance between each cytokine[20]. Therefore, the
219 IFN- γ /IL-4 ratio is of great significance. Furthermore, the mononuclear macrophage
220 system is divided into M1- and M2-type responses and is regulated by the Th1/Th2
221 immune status. Proinflammatory M1-type macrophages are polarized by binding to
222 lipopolysaccharide (LPS) or Th1-type cytokines (such as IFN- γ), producing
223 proinflammatory cytokines including IL-1 β , IL- 23, TNF- α ; anti-inflammatory M2
224 macrophages are polarized by Th2-related cytokines, such as IL-4 and IL-13, and
225 secrete anti-inflammatory cytokines such as IL-10 and TGF- β [21], promoting tissue
226 healing and inflammation resolution[22]. Therefore, the M1/M2 type immune response
227 can be evaluated by the TNF- α /IL-4 ratio and the TNF- α /IL-10 ratio.

228 In this study, by collecting laboratory test results, imaging data, and medical
229 history, we discovered that the levels of various inflammatory factors and immune
230 status in patients with acute cerebral infarction were affected by the infarct size.

231 The infarct size significantly affects the immune system. While several studies
232 have focused on the effect of infarct size on adaptive immune function impairment, we
233 explored its effects on the immune status and the balance between proinflammatory and
234 anti-inflammatory responses. Fluctuations in various cytokine levels in the peripheral
235 circulation can reflect changes in peripheral immunity following stroke. Our results
236 showed that the levels of cytokines (IFN- γ , TNF- α , IL-2, IL-4, IL-6, IL10, IL-17A)
237 were significantly higher in the group with large-area cerebral infarction than those in
238 non-large-area cerebral infarction group; however, the extent of increase varied for each
239 cytokine. Furthermore, compared to the baseline-matched non-large cerebral infarction
240 group, the absolute value and percentage of lymphocytes decreased significantly in
241 patients with large cerebral infarctions; however, the NLR was significantly higher in
242 the large-area cerebral infarction group. Neutrophils are crucial in innate immunity, and

243 the NLR reflects the degree of immune disorder. A higher NLR indicated a greater
244 degree of adaptive immunity impairment. Our findings suggest that patients with large-
245 area cerebral infarctions have more impaired adaptive immune functions, and the
246 relative levels of cytokines affect the immune status (adaptive immunity). Additionally,
247 we calculated the IFN- γ /IL-4, TNF- α /IL-4, and TNF- α /IL-10 ratios. The data showed
248 that the TNF- α /IL-4 ratio was significantly decreased in the group with large-area
249 cerebral infarction, indicating a more anti-inflammatory balance. Notably, the IFN-
250 γ /IL-4 and TNF- α /IL-10 ratios were decreased, suggesting a shift towards an anti-
251 inflammatory response in patients with severe infarction.

252 The immune response is involved throughout cerebral infarction and plays an
253 important role in the process of disease transformation with a great degree of variation.
254 Therefore, it is a potential target for improving the prognosis and outcomes of
255 neurological function. However, at present, there is no systematic research on the
256 effects of the infarct volume on cytokines in patients with acute ischemic stroke, and
257 there is a lack of a deeper understanding of the impact of the immune status on clinical
258 adverse events. Cerebral infarction is a complex disease; several conditions induce it,
259 and the pathological mechanism after its onset is complicated.

260 This study collected first-hand clinical information on patients and systematically
261 analyzed that severity of infarction may affect the serum cytokine levels and immune
262 status of patients with acute cerebral infarction, and explored how it regulates immunity.
263 This study provides valuable clinical data for related fields and enables the clinicians
264 to make informed decisions in selecting immunotherapy approaches and tailor
265 rehabilitation strategies to optimize patient outcomes by considering different infarct
266 sizes.

267

268

269

270 **Acknowledgment**

271 We are highly thankful to Bethune First Hospital of Jilin University, Professor Ms. Wang, and
272 Professor Ms.Ma for guiding us to finalize this article.Thanks to Xingqi Su, Lingmin Zhao,Julin
273 You,LiangShu Feng,LiChong Zhu,Ying Chen,YuLei Hao,XinYu Wang ,JiaChun Feng,the above
274 authors for their joint efforts.

275

276 **Funding**

277 None.

278

279 **Data availability**

280 The data that support the findings of this study are available from the corresponding author
281 upon reasonable request.

282

283 **ethics statements**

284 The Ethics Committee of the First Hospital of Jilin University reviewed and approved the study,
285 ensuring that it adhered to ethical principles and guidelines for human subject research. The
286 approval number AF-IRB-032-02 indicates that the study has undergone thorough ethical scrutiny
287 and met the necessary requirements.

288

289 The participants were provided with detailed information about the study, including its purpose,
290 procedures, potential risks and benefits, confidentiality measures, and their rights as participants.
291 They were given ample time to ask questions and clarify any concerns before voluntarily signing
292 the consent form.

293

294 The written informed consent form documented the participant's agreement to participate in
295 the study and their understanding of the information provided. It also stated that they could
296 withdraw from the study at any time without penalty.

297


298 To ensure confidentiality, the consent forms were securely stored and accessible only to the
299 research team. Any identifying information was anonymized or coded to protect the participants'
300 privacy.The research team will continue to prioritize the welfare and rights of the participants
301 throughout the study, maintaining ethical standards and promptly addressing any concerns that
302 may arise.

303 Patients with acute ischemic stroke that presented within 72 h of onset from October 2017 to
304 October 2019 were enrolled.




305 References


- 306 1.Pan J, Li X, Peng Y. Remote ischemic conditioning for acute ischemic stroke: dawn in the
307 darkness. *Reviews in the Neurosciences*. 2016;27.
- 308 2.Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Giannarelli C. Single-cell immune
309 landscape of human atherosclerotic plaques. *Nature Medicine*. 2019;25(10).
- 310 3.Pakzad B, Rajae E, Shahrabi S, Mansournezhad S, Saki N. T-Cell Molecular Modulation
311 Responses in Atherosclerosis Anergy. *Laboratory Medicine*. 2020;(16).
- 312 4.Yi X, Zhu L, Sui G, Li J, Bao S. Inflammation and Endothelial Function Relevant Genetic
313 Polymorphisms and Carotid Plaque in Chinese Population. *Journal of Atherosclerosis and*
314 *Thrombosis*. 2020;27(9).
- 315 5.Korn T, Kallies A. T cell responses in the central nervous system. *Nature Reviews Immunology*.
316 2017;17(3):179-94. doi: 10.1038/nri.2016.144.
- 317 6.Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM, et al. Autoimmune responses to
318 the brain after stroke are associated with worse outcome. *Stroke*. 2011;42(10):2763-9. Epub
319 20110728. doi: 10.1161/strokeaha.111.619593.
- 320 7.Ren H, Liu X, Wang L, Gao Y. Lymphocyte-to-Monocyte Ratio: A Novel Predictor of the
321 Prognosis of Acute Ischemic Stroke. *J Stroke Cerebrovasc Dis*. 2017;26(11):2595-
322 602.Epub20170826.doi:10.1016/j.jstrokecerebrovasdis.2017.06.019.
- 323 8.Nam KW, Kim TJ, Lee JS, Kwon HM, Lee YS, Ko SB, et al. High Neutrophil-to-Lymphocyte
324 Ratio Predicts Stroke-Associated Pneumonia. *Stroke*. 2018;49(8):1886-92. doi:
325 10.1161/strokeaha.118.021228.
- 326 9.Wang Y, Zhang JH, Sheng J, Shao A. Immunoreactive Cells After Cerebral Ischemia. *Front*
327 *Immunol*.2019;10:2781.Epub 20191126. doi:10.3389/fimmu.2019.02781.
- 328 10.Jian Z, Liu R, Zhu X, Smerin D, Zhong Y, Gu L, et al. The Involvement and Therapy Target of
329 Immune Cells After Ischemic Stroke. *Front Immunol*. 2019;10:2167. Epub 20190911. doi:
330 10.3389/fimmu.2019.02167.
- 331 11.Saino O, Taguchi A, Nakagomi T, Nakano-Doi A, Kashiwamura S, Doe N, et al.
332 Immunodeficiency reduces neural stem/progenitor cell apoptosis and enhances neurogenesis in the
333 cerebral cortex after stroke. *J Neurosci Res*. 2010;88(11):2385-97. doi: 10.1002/jnr.22410.
- 334 12.Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, et al. Microglia activated
335 by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult
336 stem/progenitor cells. *Mol Cell Neurosci*. 2006;31(1):149-60. Epub 20051116. doi:
337 10.1016/j.mcn.2005.10.006.
- 338 13.Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of
339 angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy
340 approach.*Am J Pathol*.2000;156(4):1381-93.doi: 10.1016/s0002-9440(10)65007-9.
- 341 14.Wang S, Zhang H, Xu Y. Crosstalk between microglia and T cells contributes to brain damage
342 and recovery after ischemic stroke. *Neurol Res*. 2016;38(6):495-503. Epub 20160531. doi:
343 10.1080/01616412.2016.1188473.
- 344 15.Cramer JV, Benakis C, Liesz A. T cells in the post-ischemic brain: Troopers or paramedics?J
345 *Neuroimmunol*. 2019;326:33-7. Epub 20181113. doi: 10.1016/j.jneuroim.2018.11.006.
- 346 16.Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic
347 stroke: translational insights from experimental studies. *J Cereb Blood Flow Metab*.

- 348 2015;35(6):888-901. Epub 20150325. doi: 10.1038/jcbfm.2015.45.
349 17.Maestroni GJ. Sympathetic nervous system influence on the innate immune response. *Ann N Y*
350 *Acad Sci.* 2006;1069:195-207. doi: 10.1196/annals.1351.017.
351 18.Yuan M, Han B, Xia Y, Liu Y, Wang C, Zhang C. Augmentation of peripheral lymphocyte-
352 derived cholinergic activity in patients with acute ischemic stroke. *BMC Neurol.* 2019;19(1):236.
353 Epub 20191015. doi: 10.1186/s12883-019-1481-5.
354 19.Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency
355 promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by
356 poststroke T helper cell type 1-like immunostimulation. *J Exp Med.* 2003;198(5):725-36. Epub
357 20030825. doi: 10.1084/jem.20021098.
358 20.Sekiya T, Yoshimura A. In Vitro Th Differentiation Protocol. *Methods Mol Biol.*
359 2016;1344:183-91. doi: 10.1007/978-1-4939-2966-5_10.
360 21.Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F,
361 et al. Macrophage plasticity, polarization, and function in health and disease. *J Cell Physiol.*
362 2018;233(9):6425-40. Epub 20180301. doi: 10.1002/jcp.26429.
363 22.Tschoe C, Bushnell CD, Duncan PW, Alexander-Miller MA, Wolfe SQ. Neuroinflammation
364 after Intracerebral Hemorrhage and Potential Therapeutic Targets. *J Stroke.* 2020;22(1):29-46. Epub
365 20200131. doi: 10.5853/jos.2019.02236.
366
367
368
369



medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






Fig 1



medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






Fig 2



medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Fig 7